Progressive Supranuclear Palsy
Conditions
Interventions
investigational material(s)
Generic name etc : BMS-986168
INN of investigational material :
Therapeutic category code : 119 Other agents affecting central nervous system
Dosage and Administration for
Sponsors
Bristol-Myers Squibb K.K.
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Participants with probable or possible PSP Able to ambulate independently or with assistance Able to tolerate MRI Have reliable caregiver to accompany participant to all study visits Score greater or equal to 20 on the Mini Mental State Exam (MMSE) at screening Participant must reside outside a skilled nursing facility or dementia care facility at the time of screening and admission to such a facility must not be planned Other protocol defined inclusion/exclusion criteria could apply.
Exclusion criteria
Exclusion criteria: Presence of other significant neurological or psychiatric disorders Diagnosis of amyotrophic lateral sclerosis (ALS) or other motor neuron disease History of early, prominent rapid eye movement (REM) sleep behavior disorder History of or screening brain MRI scan indicative of significant abnormality Known history of serum or plasma progranulin level less than one standard deviation below the normal patient mean for the laboratory performing the assay Other protocol defined inclusion/exclusion criteria could apply.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in PSP (Progressive Supranuclear Palsy) Rating Scale [ Time Frame: Up to 52 Weeks ] Change from baseline Frequency of Adverse Events [ Time Frame: Up to 52 Weeks ] Numbers and Percentages | — |
Outcome results
None listed